Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RU-486 safety profile

Executive Summary

FDA has "received a few letters about RU-486 expressing concerns about potential new safety risks," Commissioner McClellan says during National Press Club address Aug. 8. "We are carefully evaluating all of that information." The abortifacient is marketed by Danco as Mifeprex; the Bush Administration's theme since taking office has been that FDA will keep an eye on the safety of the drug as it would for any other marketed product (1"The Pink Sheet" Sept. 30, 2002, p. 6)...
Advertisement

Related Content

FDA Ad Policies Will Be One Issue In Commissioner Confirmation Process
FDA Ad Policies Will Be One Issue In Commissioner Confirmation Process
Advertisement
UsernamePublicRestriction

Register

PS042298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel